Thus, controlling the AT1R activation and inhibiting the p-FAK/NOX2 signaling pathway can be beneficial to the prevention and treatment of DCM, providing the inspiration for further study of the pharmacological mechanisms of Dapa. The gene discussed is PTK2; the disease is familial dilated cardiomyopathy.